Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADME and Bioavailability Study of Brigimadlin in Advanced Solid Tumors
NCT05613036Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jan 2023
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of brigimadlin in solid tumor (2 cohorts), sponsored by Boehringer Ingelheim. Primary endpoints: Fraction of [14C]-radioactivity excreted in urine up to 36 days, Fraction of [14C]-radioactivity excreted in faeces up to 36 days and 2 more. Started Jan 2023; status: completed.
02
Drugs
brigimadlin
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05613036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05613036.